Lv5
1425 积分 2021-02-17 加入
Nusinersen induces detectable changes in compound motor action potential response in spinal muscular atrophy type 1 patients with severe impairment of motor function
1个月前
已完结
A new score combining compound muscle action potential (CMAP) amplitudes and motor score is predictive of motor outcome after AVXS-101 (Onasemnogene Abeparvovec) SMA therapy
7个月前
已完结
RESEARCH ARTICLE|ARTICLES IN PRESS Purchase Subscribe Save Share Reprints Request Effect of Nusinersen Treatment on Quality of Life and Motor Function in Adult Patients with Spinal Muscular Atrophy
10个月前
已完结
Impact of nusinersen on the health-related quality of life and caregiver burden of patients with spinal muscular atrophy with symptom onset after age 6 months
1年前
已完结
A new score combining compound muscle action potential (CMAP) amplitudes and motor score is predictive of motor outcome after AVXS-101 (Onasemnogene Abeparvovec) SMA therapy
1年前
已完结
Use of the assessment of caregiver experience with neuromuscular disease (ACEND with SMA) - a caregiver experience from a single center
1年前
已完结
Systematic Review of Motor Function Scales and Patient-Reported Outcomes in Spinal Muscular Atrophy
1年前
已完结
Real-World Data: Risdiplam (Evrysdi) in Three Patients with SMA Type II: Single-Center Experiences
1年前
已关闭
Assessment of Bulbar Function in Adult Patients with 5q-SMA Type 2 and 3 under Treatment with Nusinersen
1年前
已完结
How children and caregivers viewed the change from nusinersen to risdiplam for treating spinal muscular atrophy
1年前
已完结
皖公网安备34019202002308
